Clik here to view.
Roche strikes neuro-focused partnership with RNA exon editing startup Ascidian
Roche has tapped a small Boston startup for access to a sweeping form of RNA editing that replaces large swathes of errant genetic code. Broadly known as RNA writing, scientists have said the...
View ArticleClik here to view.
Hikma to take over several assets from Xellia, including a US manufacturing site
Generic drug company Hikma is bolstering its portfolio by acquiring parts of Xellia Pharmaceuticals’ finished dosage form business in the US. This includes Hikma taking on a manufacturing site as well...
View ArticleA new obesity biotech; UroGen aims to raise $107M
Plus, news about Otsuka, Ionis, Ability Biologics, Santhera, Mustang Bio and Vaxart: New biotech joins obesity race: Supercede Therapeutics raised an undisclosed seed round from an unnamed investor to...
View ArticleClik here to view.
Day One enters ADC field, going after a target that once attracted AbbVie and...
Shortly after securing its first FDA approval and bagging $108 million from a priority review voucher sale, Day One Biopharmaceuticals is entering the hottest pocket of oncology drug development —...
View ArticleClik here to view.
After two patient deaths from presumed sepsis, FDA puts partial hold on...
The FDA put three clinical studies of Zentalis’ WEE1 inhibitor on partial hold following two patient deaths likely from sepsis in one study earlier this year. The two patients were part of the Phase 2...
View ArticleTaysha teases early gene therapy data for Rett syndrome
Taysha Gene Therapies’ treatment candidate for Rett syndrome has shown hints of efficacy in a handful of adult and pediatric patients enrolled in two early-phase clinical trials. The treatment, dubbed...
View ArticleClik here to view.
Intra-Cellular reports a depression win, setting up future competition with...
Intra-Cellular Therapies has nailed a second Phase 3 study testing its antipsychotic medication Caplyta as an adjunctive treatment for major depression. Next, it plans to go to the FDA in the second...
View ArticleTeva and US government discuss settling kickback lawsuit over Copaxone
Teva and the US government are in talks to settle a lawsuit against the company alleging a kickback scheme for its blockbuster multiple sclerosis drug Copaxone. In court documents filed over the...
View ArticleFTC backs plan to target more patent settlements it sees as anticompetitive
The Federal Trade Commission on Tuesday offered up support for a proposed rule from the US Patent and Trademark Office that could help regulators more closely track pharma patent settlements that might...
View ArticleClik here to view.
FDA loosens side effect reporting requirements for some CAR-T therapies
The FDA is no longer requiring the reporting of two common — and sometimes serious — side effects for a handful of CAR-T therapies in an effort “to minimize the burden on the healthcare delivery...
View ArticleInternational society criticizes Utah law for permitting unapproved stem cell...
The International Society for Cell and Gene Therapy is pushing back against a Utah law that allows healthcare providers to treat patients with placental stem cell therapies that haven’t been approved...
View ArticleClik here to view.
AbbVie adds ulcerative colitis to Skyrizi label
The FDA approved AbbVie’s Skyrizi to treat moderate to severe ulcerative colitis, adding another indication to the immunology drug’s arsenal. Rick Gonzalez AbbVie has said that UC patients make up...
View ArticleThree healthcare SPACs reveal their IPO plans
SPACs might never fully go away if the ambitions of three new healthcare-focused shops have any sway. As initial public offerings are far and few between, and even reverse mergers have fallen by the...
View ArticleSamsung Bio and Baxter dial up manufacturing deal to $223M
Baxter Healthcare will pay Samsung Biologics an extra $208 million to manufacture certain drug products until the end of 2034 in a revised manufacturing contract. This is at least the third agreement...
View ArticleClik here to view.
iOnctura raises €80M in Series B to advance rare eye cancer treatment
iOnctura has collected €80 million ($85.9 million) in a Series B round to support its lead cancer candidate through a Phase 2 test in uveal melanoma and expand its development to other indications. The...
View ArticleEli Lilly sues more compounders over ‘deceptive’ tirzepatide claims
Eli Lilly is filing a fresh round of lawsuits against medspas, wellness centers and other entities that it claims are selling compounded versions of its tirzepatide-based drugs Mounjaro and Zepbound....
View ArticleGilead tested an antibody many times. Āshibio salvages it, with $40M and...
Gilead had tested a humanized antibody called andecaliximab, or GS-5745, in close to 1,000 patients before giving up on it a few years ago. The company had multiple mid- and late-stage attempts in...
View ArticleAphaia targets prediabetes with oral glucose drug
The idea behind Aphaia Pharma is to treat metabolic disease early enough that patients don’t progress to a type 2 diabetes diagnosis. The company is developing an oral glucose treatment targeting...
View ArticleForbion's new €75M fund; Cara Therapeutics to cut workforce after trial failure
Plus, news about Cinclus Pharma, Biophytis and Blanver: Forbion’s new fund: The Dutch VC firm’s BioEconomy Fund I closed €75 million (about $80 million) to invest in sustainable startups across food,...
View ArticleClik here to view.
Silence’s siRNA candidate for cardiovascular disease continues to deliver in...
Silence Therapeutics has unveiled additional data from a mid-stage trial of its siRNA therapy candidate in certain people at risk of heart episodes, setting the stage for potential registrational...
View Article